Omega Total Debt

OMGA
 Stock
  

USD 6.47  0.44  7.30%   

Omega Therapeutics fundamentals help investors to digest information that contributes to Omega Therapeutics' financial success or failures. It also enables traders to predict the movement of Omega Stock. The fundamental analysis module provides a way to measure Omega Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Omega Therapeutics stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Omega Total Debt Analysis

Omega Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Total Debt 
 = 
Bonds 
+  
Notes 
More About Total Debt | All Equity Analysis

Current Omega Therapeutics Total Debt

    
  23.38 M  
Most of Omega Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Omega Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Compare to competition

Based on the latest financial disclosure, Omega Therapeutics has a Total Debt of 23.38 M. This is 99.15% lower than that of the Healthcare sector and 92.8% lower than that of the Biotechnology industry. The total debt for all United States stocks is 99.56% higher than that of the company.
Omega Therapeutics is rated top company in total debt category among related companies. Total debt of Biotechnology industry is now estimated at about 46.76 Million. Omega Therapeutics totals roughly 23.38 Million in total debt claiming about 50% of stocks in Biotechnology industry.
Total debt  Capitalization  Workforce  Revenue  Valuation

Omega Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Omega Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Omega Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Omega Therapeutics' value.
Security TypeSharesValue
Flagship Pioneering IncCommon Shares25.9 M98.4 M
Fmr LlcCommon Shares4.4 M16.7 M
Harbourvest Partners LlcCommon Shares2.6 M10.1 M
Artal Group SaCommon Shares2.3 M8.6 M
State Of Wisconsin Investment BoardCommon Shares1.9 M7.1 M
Chi Advisors LlcCommon Shares1.1 MM
Vanguard Group IncCommon Shares749.6 K2.8 M

Omega Fundamentals

About Omega Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Omega Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Omega Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Omega Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Omega Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Omega Therapeutics' short interest history, or implied volatility extrapolated from Omega Therapeutics options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Omega Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Omega Therapeutics Piotroski F Score and Omega Therapeutics Altman Z Score analysis. Note that the Omega Therapeutics information on this page should be used as a complementary analysis to other Omega Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Omega Stock analysis

When running Omega Therapeutics price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.